Sponsors (32)
Introduced July 7, 2025 by Gregory Francis Murphy · Last progress July 7, 2025
The bill redirects larger manufacturer rebates to shore up Medicare Part B finances and standardizes payment rules—potentially lowering some beneficiaries' out-of-pocket drug costs—while imposing higher manufacturer rebates and administrative burdens that could raise prices, limit access, or leave some patients with substantial coinsurance.
Taxpayers and Medicare beneficiaries: additional manufacturer rebate revenue is redirected into the Medicare Part B trust fund, which can lower federal program net costs and help support Part B solvency.
Medicare beneficiaries: coinsurance for certain Part B drugs may be lower because patient cost-sharing is tied to MFP+6, potentially reducing out-of-pocket drug costs for affected enrollees.
Hospitals, health systems, and CMS: the bill removes a carve-out and aligns Part B payment methodology across drugs, increasing payment consistency and reducing special-case complexity for administration.
Manufacturers (and Medicare patients): manufacturers must remit substantial quarterly rebates, which could incentivize higher list prices, reduce product availability, or delay introductions for the Medicare market.
Medicare beneficiaries: some enrollees will still owe 20% coinsurance based on MFP+6, which can remain large for high-cost therapies and may not eliminate significant out-of-pocket spending.
Manufacturers, hospitals, and payors: increased administrative reporting and enforcement will raise compliance costs for manufacturers and providers (and for CMS/GSA), potentially shifting costs to payors or consumers.
Based on analysis of 2 sections of legislative text.
Selected drugs under the MFP program are moved onto standard Medicare Part B ASP+6 payment, with new quarterly manufacturer rebates and MFP-based beneficiary coinsurance subject to an inflation/rebate cap.
Changes Medicare Part B payment rules for drugs and biologics designated under the Maximum Fair Price (MFP) negotiation program by removing a prior carve-out and subjecting those products to the standard ASP+6 payment methodology. It also creates a new quarterly reporting and manufacturer rebate requirement tied to MFP-designated drugs and adjusts beneficiary coinsurance to be based on an MFP+6 amount with limits tied to inflation/rebate interactions.